The Manufacturers Life Insurance Company Sells 136,588 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

The Manufacturers Life Insurance Company lowered its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 82.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,333 shares of the company’s stock after selling 136,588 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Autolus Therapeutics were worth $67,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in AUTL. Wellington Management Group LLP increased its stake in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after buying an additional 1,125,454 shares during the last quarter. Candriam S.C.A. bought a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $7,500,000. BIT Capital GmbH increased its position in shares of Autolus Therapeutics by 147.0% in the fourth quarter. BIT Capital GmbH now owns 636,979 shares of the company’s stock valued at $1,497,000 after acquiring an additional 379,050 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Autolus Therapeutics by 146.7% during the fourth quarter. Renaissance Technologies LLC now owns 618,942 shares of the company’s stock worth $1,455,000 after acquiring an additional 368,071 shares in the last quarter. Finally, HealthInvest Partners AB boosted its position in Autolus Therapeutics by 8.4% during the fourth quarter. HealthInvest Partners AB now owns 479,644 shares of the company’s stock valued at $1,060,000 after purchasing an additional 37,221 shares during the last quarter. 72.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on AUTL. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Wells Fargo & Company lowered their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st. Finally, Truist Financial cut their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $9.32.

Autolus Therapeutics Price Performance

AUTL stock opened at $1.48 on Tuesday. Autolus Therapeutics plc has a one year low of $1.11 and a one year high of $5.00. The stock has a market cap of $393.89 million, a price-to-earnings ratio of -1.22 and a beta of 1.77. The company has a fifty day moving average price of $1.45 and a two-hundred day moving average price of $2.11.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. Research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.